Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 96Carcinoma, Non-Small-Cell Lung 86Prostatic Neoplasms 75Multiple Myeloma 75Neoplasms 50Leukemia, Myeloid, Acute 44Lymphoma 43Melanoma 42Neoplasm Metastasis 39Ovarian Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Lymphoma, Non-Hodgkin 34Lung Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 29Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Fallopian Tube Neoplasms 21Carcinoma, Renal Cell 21Sarcoma 20Lymphoma, Follicular 20Urinary Bladder Neoplasms 18Recurrence 18Lymphoma, Mantle-Cell 18Head and Neck Neoplasms 18Brain Neoplasms 18

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cytokine Release Syndrome × 90 days × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡